en · de · es · fr · pt
peptide-index.peptides7501.com › Faq › Background And Mechanism — Beginner to Advanced

Background And Mechanism — Beginner to Advanced

By Editorial Desk · published 2025-08-01 · last reviewed 2025-08-31 · Faq

Everything below concerns NR1D2. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-08-31. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

SR9009 Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Related pages on this site

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Supporting material

=== Visas === Seeking to reverse a policy of Bolsonaro — which, according to the current government, made the decision to "break with the pattern of Brazilian migration policy, historically grounded in the principles of reciprocity and equal treatment" — the government instructed the Itamaraty to once again require visas for entry into Brazil by citizens of Australia, Canada, the United States, and Japan, just as these countries already do when it comes to Brazilian citizens. The decision was taken after consultations with the governments of these four countries regarding the possibility of also exempting Brazilians from visas, in accordance with the principle of reciprocity; a principle that the Ministry of Foreign Affairs had already defended since 2017, when it opposed a proposal by the Ministry of Tourism to permanently remove the visa requirement for these countries. The Itamaraty's decision had also taken into account a decree issued by then president Donald Trump in January 2017, intended to complicate the granting of visas to citizens of several countries, among which Brazil was included.

== Adverse effects == Immunotherapies as a group have off-target effects and toxicities common to them. Some of these include interstitial pneumonitis, colitis, hepatitis, thyroiditis, skin reactions, low levels of platelets and white blood cells, inflammation of the brain or spinal cord, neuromuscular adverse events including myositis, Guillain–Barré syndrome, myasthenia gravis; myocarditis and cardiac insufficiency, acute adrenal insufficiency, and nephritis. The most common kidney related changes are acute interstitial nephritis, followed by glomerular diseases and then tubular damage. The detailed mechanism of these adverse effects are not fully elucidated; however, they are clearly different from known autoimmune diseases. Immune-mediated adverse reactions are usually attributed to generalised dysregulation of T cells or development of autoantibodies, although memory T cell responses against occult viral infections might also play a role in some patients with advanced melanoma following combined PD-1/CTLA-4 blockade. When compared with standard chemotherapeutic agents, PD-1/PD-L1 inhibitors had a lower reported incidence of fatigue, sensory neuropathy, diarrhea, bone marrow suppression, loss of appetite, nausea, and constipation.

=== Infectious hypotheses === One hypothesis suggests that prenatal viral infection may contribute to the development of autism. Prenatal exposure to rubella or cytomegalovirus activates the mother's immune response and may greatly increase the risk for autism in mice. Congenital rubella syndrome is the most convincing environmental cause of autism. Infection-associated immunological events in early pregnancy may affect neural development more than infections in late pregnancy, not only for autism, but also for psychiatric disorders of presumed neurodevelopmental origin, notably schizophrenia. A 2021 meta-analysis of 36 studies suggested a relationship between mothers recalling an infection during pregnancy and having children with autism.

Sources: en.wikipedia.org

Notes from published material

In linguistics, particularly in syntax, an element is described as in situ when it is pronounced in the same position where it receives its semantic interpretation. This concept is especially relevant in the analysis of wh- questions across languages. For example, in Mandarin Chinese and Kurdish, wh-elements remain in situ, producing structures analogous to "John bought what?" where the interrogative word occupies the same syntactic position as the direct object would in a declarative sentence ("John bought bread"). By contrast, languages like English and French typically employ wh-movement, where the interrogative element is displaced from its base position to the beginning of the clause, as in "What did John buy?" Here, the wh-word what has moved from its original post-verbal position to the sentence-initial position, leaving behind a trace or gap in the object position. This typological distinction between in situ wh-elements and moved wh-elements represents one of the fundamental parameters of variation in natural language syntax and has been extensively studied within generative grammar frameworks.

== Principles of Desalting and Buffer Exchange == Size exclusion chromatography applications for separating macromolecules based on subtle differences in size typically use resins with large and varied pore sizes in long chromatography columns. However, for buffer exchange and desalting applications, it is mainly the maximum effective pore size (exclusion limit or molecular weight cut off (MWCO) of the resin) that determines the size of molecules that can be separated. Molecules that are significantly smaller than the MWCO penetrate into the pores of the resin, while molecules larger than the MWCO are unable to enter the pores and remain together in the void volume of the column. By passing samples through a column resin bed with sufficient length and volume, macromolecules can be fully separated from small molecules that travel a greater distance though the pores of the resin bed. No significant separation of molecules larger than the exclusion limit occurs. In order for the desired macromolecules to remain in the void volume, resins with very small pores sizes must be utilized. For typical desalting and buffer exchange applications choosing a resin with a molecular weight cut off between 5 and 10KDa is usually best. For other applications, such as separating peptides from full-sized proteins, resins with larger exclusion limits may be necessary. The macromolecular components are recovered in the buffer used to pre-equilibrate the gel-filtration matrix, while the small molecules can be collected in a later fraction volume or be left trapped in the resin.

The tumultuous reception that Sfeir received not only signified a historic reconciliation between Maronites and Druze, who fought a war in 1983–1984, but underscored the fact that the banner of Lebanese sovereignty had broad multi-confessional appeal and was a cornerstone for the Cedar Revolution in 2005. For historical and political reasons, social and economic conditions vary among Lebanon's sects. Christians in Beirut dominated the most lucrative financial and commercial sectors, while Muslims had a significant presence in lower value-added industrial sectors. Muslims generally comprised the majority of the working class, while Christians predominated in the middle and upper classes (about 75%), also owning most small and medium-sized enterprises. Researcher Gordon observed that in 1980, the financial income of Christians was approximately 16% higher than that of the Druze and about 58% higher than that of the Shiites.

The presence of a phosphoryl group in a part of a protein may depend on the folding of the enzyme (which can make the protein more or less accessible to kinase proteins) and the proximity of other phosphoryl groups.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

Network